Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026
Rhea-AI Summary
Lyell Immunopharma (Nasdaq: LYEL) announced that senior management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on June 8, 2026, in Miami, Florida.
A fireside chat is scheduled for 11:20 a.m. ET, with a live webcast and replay available in the Investors section of Lyell’s website.
Positive
- None.
Negative
- None.
News Market Reaction – LYEL
In the Jun 1 session, LYEL declined 1.04%, reflecting a mild negative market reaction. Argus tracked a trough of -8.6% from its starting point during tracking. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 12 | Investor conferences | Neutral | +0.3% | Announced participation in two May 2026 oncology-focused investor conferences. |
| May 06 | Q1 2026 earnings | Positive | -3.8% | Reported Q1 2026 results, clinical milestones and cash funding into Q3 2027. |
| Apr 07 | Needham conference | Neutral | +0.4% | Outlined CAR T-cell pipeline at Needham virtual healthcare conference with webcast. |
| Mar 12 | Q4/FY 2025 results | Negative | -14.2% | Reported large 2025 net loss and cash position alongside pipeline trial updates. |
| Mar 09 | Private placement tranche | Positive | +13.5% | Closed additional $50M equity tranche after clinical milestone and named new CFO/CB0. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings and financing updates have driven the largest moves (both up and down), while conference participation headlines have historically coincided with only modest price changes.
Over the past six months, LYEL has mixed catalysts. Investor conference announcements on Apr 14, 2026 and in May 2026 saw only small moves, suggesting routine visibility events. In contrast, earnings and financing updates on Mar 9, Mar 12 and May 6, 2026 produced double‑digit reactions, both positive and negative, tied to private placement funding, sizable net losses, and updated cash runway. Today’s conference participation fits the pattern of lower-impact, investor-relations oriented news rather than a major clinical or financial inflection.
Key Terms
chimeric antigen receptor (car) t-cell therapies medical
nasdaq financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on Monday, June 8, 2026, in Miami, Florida, with a fireside chat scheduled for 11:20 am Eastern Time.
A live webcast of the fireside chat and subsequent replay can be accessed through the Investors section of the Company’s website at www.lyell.com.
About Lyell Immunopharma, Inc.
Lyell is a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to arm CAR T cells with enhancements needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness and function in the hostile tumor microenvironment. LyFE has commercial launch capability and is expected to have the capacity to manufacture more than 1,200 CAR T-cell doses per year. To learn more, please visit www.lyell.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: Lyell management’s planned participation at an investor conference; the potential clinical benefits and therapeutic potential of Lyell’s product candidates; and the sufficiency of the capacity of LyFE to manufacture drug supply through potential commercial launch. These statements are based on Lyell’s current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties described under the heading “Risk Factors” in Lyell’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the Securities and Exchange Commission on May 6, 2026. Forward-looking statements contained in this press release are made as of this date, and Lyell undertakes no duty to update such information except as required under applicable law.
Contact:
Pablo Fenton
Associate Director, Investor Relations and Corporate Communications
pfenton@lyell.com
